Could a cancer drug tame rare clotting disorder?
NCT ID NCT05671757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether daratumumab, a drug used for certain cancers, is safe for people with antiphospholipid syndrome (APS), an autoimmune disorder that raises blood clot risk. Up to 22 adults will receive weekly infusions for 8 weeks at different doses. The main goal is to check for serious side effects during dose escalation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab (a drug that targets immune cells)
What this could lead to
If safe and effective, daratumumab could offer a new treatment option for antiphospholipid syndrome, reducing blood clot risk.
What could go wrong
This is a very early, small safety trial (phase 1b/2) with only 22 participants. It may not show benefit, and side effects like infections or allergic reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital for Special Surgery
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic Rochester
COMPLETEDRochester, Minnesota, 55905, United States
-
NYU Langone
RECRUITINGNew York, New York, 10016, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwell Health
RECRUITINGGreat Neck, New York, 11021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••